NEW YORK, June 16 (Reuters) - Shares of Savient Pharmaceuticals Inc (SVNT.O) rose 28.4 percent to $11.90 after the bell on Tuesday after a U.S. advisory panel urged the approval of the company's experimental gout drug.
Savient's shares had been halted ahead of the committee's vote and closed at $9.27. For details, see [ID:nN16298974]
(Reporting by Leah Schnurr)
WASHINGTON (Reuters) - Senate Democratic healthcare negotiators said they agreed on Tuesday to replace a government-run insurance option with a scaled-back non-profit plan and would seek cost estimates on the deal.
Mount Kilimanjaro's melting snow cap is one of many things forever altered by climate change. Here's a snapshot of a world dealing with environmental destruction. Full Article
War is just about the only story to tell in Somalia. But when one reporter tried to cover an event reflecting positive change, violence reared its ugly head again. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
